Takeda Pharmaceutical has been on a tear over the past few weeks, striking deals to develop new therapies for various diseases. Now the Japan-based pharma powerhouse has announced a multi-year drug discovery deal with Charles River Laboratories.
Takeda Pharmaceutical Co. trimmed the company’s full-year fiscal 2019 loss forecast on strong sales of core drugs and progress in consolidating with Shire Plc.
Evotec SE announced a strategic multi-year collaboration with Takeda Pharmaceutical Company Limited to establish at least five drug discovery programs across multiple therapeutic areas.
Bausch Health Companies Inc. was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
Understanding the nuances behind why a physician makes a decision regarding an information source when making a clinical decision is key to learning the best way to deliver content that will prompt an engagement.
Allergan struck a $200 million deal to snag Motus Therapeutics in an effort to shore up its gastrointestinal therapies.
Understanding the nuances of your brand’s healthcare professional audience(s) can improve marketing strategies and make your media dollars work harder.
Takeda will refocus R&D on three targeted therapeutic areas – oncology, gastroenterology and CNS. Vaccines will also continue to play an important role.